Global Gastroparesis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Gastroparesis Market Size

• The Global Gastroparesis Market size was valued at USD 6.82 billion in 2024 and is expected to reach USD 9.89 billion by 2032, at a CAGR of 4.8% during the forecast period
• This growth is primarily driven by the increasing prevalence of diabetes and gastrointestinal disorders, rising awareness about gastroparesis management, and the availability of advanced treatment options such as gastric electric stimulation and botulinum toxin therapy

Gastroparesis Market Analysis

• Gastroparesis is a chronic gastrointestinal disorder characterized by delayed gastric emptying without mechanical obstruction. It leads to symptoms such as nausea, vomiting, bloating, and abdominal pain, requiring both medical and surgical management strategies
• The demand for effective treatments is significantly driven by the global rise in diabetes cases, which is the leading cause of gastroparesis, along with growing diagnosis rates and improved treatment accessibility
• North America is expected to dominate the gastroparesis market due to advanced healthcare infrastructure, higher prevalence of diabetes, and early adoption of innovative therapies
• Asia-Pacific is expected to be the fastest growing region in the gastroparesis market during the forecast period due to increasing healthcare awareness, growing diabetic population, and expanding access to treatment
• Diabetic gastroparesis segment is expected to dominate the market with a market share of approximately 58.6% due to its strong correlation with diabetes and rising global incidence. As the most common form of the disease, continued advancements in drug classes and surgical procedures enhance patient outcomes

Report Scope and Gastroparesis Market Segmentation

Gastroparesis Market Trends

“Advancements in Treatment Options & Personalized Therapies”

• A prominent trend in the treatment of gastroparesis is the increasing development of personalized therapies aimed at specific patient needs, such as diabetic gastroparesis and idiopathic gastroparesis
• • Advancements in drug delivery systems, botulinum toxin injections, and gastric electric stimulation are enhancing treatment efficacy, providing better management of symptoms and improving patients' quality of life
  • For instance, gastric electric stimulation has shown promise in improving gastric motility, reducing nausea, and promoting better digestion in patients with chronic gastroparesis, particularly in those with diabetes.
• These innovations are driving the demand for more targeted treatments and providing patients with more options to manage their condition effectively

Gastroparesis Market Dynamics

Driver

“Growing Prevalence of Diabetes & Gastrointestinal Disorders”

• The increasing prevalence of diabetes and gastrointestinal disorders, particularly among older adults, is significantly contributing to the rising demand for gastroparesis treatments
• Diabetic gastroparesis, a common complication of diabetes, has become one of the leading causes of delayed gastric emptying, exacerbating symptoms like nausea, vomiting, and bloating
• As diabetes rates rise globally, the demand for effective gastroparesis management solutions increases, contributing to market growth
  • For instance, In according to the World Health Organization (WHO), diabetes is expected to affect over 578 million people worldwide by 2030, significantly increasing the incidence of diabetic gastroparesis
• Consequently, this rising prevalence is driving demand for drug treatments and surgical interventions tailored to manage gastroparesis effectively

Opportunity

“Innovative Drug Therapies & Medical Devices Integration”

• The integration of innovative drug therapies with advanced medical devices presents a major opportunity for the gastroparesis market. New pharmacological treatments, such as prokinetic drugs, combined with gastric electric stimulation devices, could provide comprehensive solutions to manage symptoms more effectively
• Additionally, AI-powered diagnostic tools for more accurate identification of gastroparesis severity and progression are gaining attention, offering enhanced treatment customization
  • For instance, AI algorithms can assist in analyzing real-time data from smart gastric stimulators, optimizing treatment protocols, and improving patient outcomes.
• The convergence of pharma innovations and medical device advancements will drive significant improvements in gastroparesis management, providing new growth avenues for companies involved in these sectors

Restraint/Challenge

“High Treatment Costs & Limited Access to Advanced Care”

• The high cost of treatment options and medical devices such as gastric electric stimulators and specialized pharmaceuticals poses a significant challenge for the gastroparesis market
• These therapies, particularly those for diabetic gastroparesis, can be expensive, making them less accessible for patients in developing countries or those without sufficient insurance coverage
  • For instance, A 2024 report by the National Institutes of Health (NIH) highlighted that cost-related access issues significantly impact the availability of high-quality treatment for gastroparesis, especially in low-resource healthcare settings
• Consequently, the high costs of advanced treatments can restrict the growth potential of the gastroparesis market and create challenges for broader patient access

Gastroparesis Market Scope

The market is segmented on the basis application, product type, technology, magnification type, end user, and distribution channel.

In 2025, the diabetic gastroparesis segment is projected to dominate the market with the largest share in the application segment

The diabetic gastroparesis segment is expected to dominate the gastroparesis market with the largest share of 45.61% in 2025 due to its strong correlation with diabetes and the rising global incidence of diabetes-related complications. As the most common form of gastroparesis, advancements in drug classes, gastric electric stimulation therapies, and surgical procedures are significantly enhancing patient outcomes, driving market growth. The increasing prevalence of diabetes worldwide further contributes to its market dominance.

The prokinetic drugs segment is expected to account for the largest share during the forecast period in the drug class market

In 2025, the prokinetic drugs segment is expected to dominate the market with the largest market share of 38.45% due to their essential role in improving gastric motility and reducing symptoms of gastroparesis, particularly in diabetic patients. As the leading treatment option for managing gastroparesis, continued advancements in drug formulations and combination therapies are enhancing patient outcomes. The rising global incidence of gastroparesis, particularly diabetic gastroparesis, further drives demand for prokinetic drugs and contributes to its market dominance.

Gastroparesis Market Regional Analysis

“North America Holds the Largest Share in the Gastroparesis Market”

• North America dominates the gastroparesis market, driven by advanced healthcare infrastructure, high adoption of innovative treatments, and a strong presence of key market players
• The U.S. holds a significant share due to the high prevalence of diabetic gastroparesis, increasing demand for effective treatments, and continuous advancements in drug classes, medical devices, and surgical procedures
• The availability of well-established reimbursement policies, increasing government initiatives for disease awareness, and strong investments in research and development by leading pharmaceutical companies further strengthen the market
• In addition, the increasing number of gastroparesis diagnoses and treatment demand, coupled with a high rate of adoption of advanced therapies, is fueling market expansion across the region

“Asia-Pacific is Projected to Register the Highest CAGR in the Gastroparesis Market”

• The Asia-Pacific region is expected to witness the highest growth rate in the gastroparesis market, driven by improvements in healthcare infrastructure, increasing awareness about digestive diseases, and rising cases of diabetes-related complications.
• Countries such as China, India, and Japan are emerging as key markets due to the growing aging population and rising incidence of diabetic gastroparesis and other gastrointestinal disorders.
• Japan, with its advanced medical technology and increasing number of gastroenterologists, remains a crucial market for gastroparesis treatments. The country continues to lead in the adoption of premium medical devices and treatments for managing gastroparesis and improving patient outcomes.
• China and India, with their large populations and rising cases of diabetes, are witnessing increased government investments in healthcare and a growing demand for modern medical treatments. The expanding presence of global pharmaceutical manufacturers and improving accessibility to advanced care further contribute to market growth in the region.

Gastroparesis Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Medtronic (Ireland)
• Neurogastrx, Inc. (U.S.)
• Endologic (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• ALLERGAN (U.S.)
• Theravance Biopharma (U.S.)
• Evoke Pharma (U.S.)
• CAIRN DIAGNOSTICS (U.S.)
• Lupin Pharmaceuticals Inc. (India)
• Thermo Fisher Scientific (U.S.)
• Amneal Pharmaceuticals LLC (U.S.)
• Annora Pharma Pvt (India)
• Bristol-Myers Squibb Company (U.S.)
• bioMérieux, Inc. (France)
• Bio-Rad Laboratories, Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc (U.S.)
• Pfizer Inc (U.S.)
• Bayer AG (Germany)
• Novartis AG (Switzerland)

Latest Developments in Global Gastroparesis Market

• In August 2022, Processa Pharmaceuticals, Inc. initiated its Phase 2A clinical trial for PCS12852, enrolling its first patient with moderate to severe gastroparesis
• In February 2022, Vanda Pharmaceuticals Inc. (Vanda) shared the Phase III clinical trial outcomes, VP-VLY-686-3303, revealing the effectiveness and safety of tradipitant in addressing gastroparesis symptoms 

SKU-45021